Aptose Biosciences, Inc. - Common Shares (APTO)
APTO moved a median of -1.33% 30 minutes after news, and -1.43% by the close. How APTO actually reacts to news — the realized, point-in-time move the market made, measured across 152 labeled events over the last three years with zero look-ahead.
APTO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 145 |
| 30-min | -1.33% | 35% | 148 |
| 60-min | -1.43% | 35% | 148 |
| to close | -1.43% | 30% | 148 |
| Middle 50% of APTO reactions | -4.04% to +1.14% |
|---|---|
| Median reaction (30-min) | -1.33% |
| Measured reactions | 152 |
Half of all Aptose Biosciences, Inc. - Common Shares news events land between -4.04% and +1.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How APTO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 38 | -2.35% | 26% | -3.28% |
| Rating reiterations | 17 | -0.80% | 41% | -2.43% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how APTO ranks against every other measured name →
That’s how APTO usually reacts — get an email when it moves on news →Email me when APTO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APTO's baseline. Nothing else.
Recent APTO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial | Press release | GlobeNewswire | — | — | |
| Aptose Announces Auditor Not Standing for Re-Appointment | Press release | GlobeNewswire | — | — | |
| Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference | Press release | GlobeNewswire | — | — | |
| Form 8-K Aptose Biosciences Inc. For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 | Press release | GlobeNewswire | -20.60% | -14.07% | |
| Form 8-K Aptose Biosciences Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -20.60% | -14.07% | |
| Aptose Reports Year End 2024 Results and Corporate Highlights | Press release | GlobeNewswire | +0.90% | +0.00% | |
| Form 10-K Aptose Biosciences Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +0.30% | |
| Form 8-K Aptose Biosciences Inc. For: Mar 28 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | +0.00% | |
| Form 8-K Aptose Biosciences Inc. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | +1.96% | -2.52% | |
| Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance | Press release | GlobeNewswire | -3.06% | -3.32% | |
| Form 8-K Aptose Biosciences Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -3.06% | -3.32% | |
| Form 8-K Aptose Biosciences Inc. For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.05% | |
| Form 8-K Aptose Biosciences Inc. For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -3.16% | -7.23% | |
| Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort | Press release | GlobeNewswire | -0.30% | -19.46% | |
| Form 8-K Aptose Biosciences Inc. For: Feb 20 | SEC filing · Form 8-K | SEC EDGAR | -0.30% | -19.46% | |
| Aptose Announces Reverse Share Split | Press release | GlobeNewswire | -8.26% | -2.47% | |
| Form 8-K Aptose Biosciences Inc. For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -8.26% | -2.47% | |
| Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility | Press release | GlobeNewswire | +11.73% | +7.14% | |
| Form 8-K Aptose Biosciences Inc. For: Feb 07 | SEC filing · Form 8-K | SEC EDGAR | +11.73% | +7.14% | |
| Form 8-K Aptose Biosciences Inc. For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | +11.73% | +7.14% | |
| Form S-1 Aptose Biosciences Inc. | SEC filing · Form S-1 | SEC EDGAR | +11.73% | +7.14% | |
| Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial | Press release | GlobeNewswire | +0.76% | +8.95% | |
| Form 8-K Aptose Biosciences Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +8.95% | |
| Form 8-K Aptose Biosciences Inc. For: Feb 03 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | +0.90% | |
| Form 8-K Aptose Biosciences Inc. For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | -1.53% | -9.11% | |
| Form 8-K Aptose Biosciences Inc. For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | -3.50% | -5.04% | |
| Form 8-K Aptose Biosciences Inc. For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -2.54% | |
| Form 8-K Aptose Biosciences Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | -3.30% | |
| Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial | Press release | GlobeNewswire | +1.10% | -3.30% | |
| Form DEF 14A Aptose Biosciences Inc. For: Jan 27 | SEC filing · Form DEF | SEC EDGAR | +0.04% | -0.21% | |
| Form DEFA14A Aptose Biosciences Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.04% | -0.21% | |
| Aptose Announces Positive Decision by Nasdaq Hearings Panel | Press release | GlobeNewswire | -6.63% | +3.33% | |
| Form 8-K Aptose Biosciences Inc. For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | -6.63% | +3.33% | |
| Form PRE 14A Aptose Biosciences Inc. For: Jan 27 | SEC filing · Form PRE | SEC EDGAR | -2.49% | -1.97% | |
| Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax | Press release | GlobeNewswire | +4.73% | +2.34% | |
| Form 8-K Aptose Biosciences Inc. For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +3.79% | +4.34% | |
| Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML | Press release | GlobeNewswire | -1.89% | +0.85% | |
| Form 8-K Aptose Biosciences Inc. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +2.56% | +3.85% | |
| Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials | Press release | GlobeNewswire | +5.91% | -0.59% | |
| Form 8-K Aptose Biosciences Inc. For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | +5.91% | -0.59% | |
| Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering | Press release | GlobeNewswire | -2.16% | -3.78% | |
| Form 8-K Aptose Biosciences Inc. For: Nov 21 | SEC filing · Form 8-K | SEC EDGAR | -2.16% | -3.78% | |
| Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering | Press release | GlobeNewswire | -3.19% | +31.94% | |
| Form 8-K Aptose Biosciences Inc. For: Nov 22 | SEC filing · Form 8-K | SEC EDGAR | -3.19% | +31.94% | |
| Form EFFECT Aptose Biosciences Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.19% | +31.94% | |
| Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy | Press release | GlobeNewswire | -3.79% | -17.24% | |
| Form 8-K Aptose Biosciences Inc. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -3.79% | -17.24% | |
| Form 10-Q Aptose Biosciences Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.28% | |
| Aptose Reports Results for the Third Quarter 2024 | Press release | GlobeNewswire | -4.13% | -8.58% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APTO section they belong to.
Where else APTO is measured.
APTO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NOVONESIS B UNSP/ADR (NVZMY) | 155 | +0.05% | 57% |
| PROMETIC LIFE SCIENCE (PFSCF) | 153 | 0.00% | 34% |
| MEI Pharma, Inc. (MEIP) | 152 | +0.07% | 51% |
| Milestone Scientific, Inc. (MLSS) | 152 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aptose Biosciences, Inc. - Common Shares's median reaction calculated?
Every labeled APTO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 152 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of APTO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APTO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.